RxDoctor Payments Data

Kaitlyn Renard, APRN

Family · Murray, KYNPI 1952916827

Payments from drug & device makers

$2,228in general payments, 2019–2025

Across 118 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$406
  • AbbVie$260
  • Novo Nordisk$191
  • Lundbeck LLC$179
  • Novartis$118
  • Corium, LLC$112
  • plus $962 from 26 others

What the payments were for

  • Food & beverage$2,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,228 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$57,719
Medicare patients
295
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$84,274
FarxigaDapagliflozin Propanediol32$41,328
JardianceEmpagliflozin27$36,641
KerendiaFinerenone34$33,259
CreonLipase/Protease/Amylase15$22,995
EliquisApixaban20$20,621
MyrbetriqMirabegron11$9,315
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$7,268
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,509
Aripiprazole15$4,811
Rosuvastatin Calcium130$1,933
Albuterol Sulfate HfaAlbuterol Sulfate81$1,511
PaxlovidNirmatrelvir/Ritonavir15$1,429
Duloxetine Hcl67$1,412
Levothyroxine Sodium131$1,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$84,27477 claims
AstraZenecaFarxiga, Bevespi Aerosphere$406$46,83845 claims
Boehringer IngelheimJardiance$16$36,64127 claims
BayerKerendia$55$33,25934 claims
AbbVieCreon, Synthroid$260$24,17933 claims
PfizerEliquis, Paxlovid$17$22,05035 claims
Astellas Pharma US IncMyrbetriq$65$9,31511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Murray

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →